Phibro Animal Health Corp (PAHC) company profile
Close on Nov 17, 2026Market cap $1.42BP/E 14.4Yield 1.37%
About Phibro Animal Health
Pharmaceutical Preparations, SIC 2834
Phibro Animal Health Corporation develops, manufactures, and sells animal health and mineral nutrition products, alongside specialty industrial chemicals. The business operates across three segments: Animal Health, Mineral Nutrition, and Performance Products. Offerings include antibacterials, anticoccidials, nutritional specialty products, vaccines, vaccine adjuvants, ethanol fermentation aids, fortifying mineral diets, and chemical catalyst ingredients. The company serves livestock producers, animal feed manufacturers, wholesalers, distributors, veterinarians, and industrial clients, targeting food animals such as poultry, cattle, and swine, as well as companion animals.
The company markets approximately 790 product lines to around 4,800 customers in about 90 countries. Its operations extend across North America, Latin America, Asia Pacific, Europe, Africa, and the Middle East, with manufacturing facilities in the United States, Italy, and China. Phibro is incorporated in Delaware, though the provided text does not state a headquarters location.
Summary of the business section of Phibro Animal Health's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Phibro Animal Health Corp
- Headquarters
- Teaneck, NJ
- Address
- Glenpointe Centre East, 3rd Floor, 300 Frank W. Burr Blvd., Suite 21 07666
- Phone
- (201) 329-7300
- Website
- www.pahc.com
- Employees
- 2,605, Jun 30, 2026
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Delaware
- Fiscal year ends
- June 30
- Auditor
- PricewaterhouseCoopers LLP, Florham Park, New Jersey
Stock & identifiers
- Ticker
- PAHC
- Exchange
- Nasdaq
- IPO date
- Apr 11, 2014
- Shares outstanding
- 41M, Aug 21, 2026
- Public float
- $763.70M, Dec 31, 2025
- Filer category
- Large accelerated filer
- SEC CIK
- 1069899
- CUSIP
- 71742Q106
- ISIN
- US71742Q1067
- FIGI
- BBG000C31ZH2
- Share class FIGI
- BBG0069NW5X3
- LEI
- 549300U24SP4AF2JUX52
- EIN
- 13-1840497
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Daniel M. Bendheim | President and CEO, Director | 15,177 |
| Jack Bendheim | Executive Chairman, Director | 39,996,860 |
| Larry Lee Miller | Chief Operating Officer | 38,275 |
| Glenn David | Chief Financial Officer | 54,959 |
| Patrick Rodriguez | VP Finance and Treasurer | 1,503 |
| Judith Weinstein | See Remarks | 5,453 |
| Lisa Ann Escudero | See Remarks | 3,434 |
| Anthony Andolino | See Remarks | 1,793 |
| Jonathan BENDHEIM | Director | 5,984 |
| E. Thomas Corcoran | Director | 41,459 |
| Joyce J. Lee | Director | – |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2026 | $5.23M | $5.20M | $1.48M | $123 | $136 |
| FY2025 | $5.28M | $5.12M | $1.47M | $111 | $99 |
| FY2024 | $4.75M | $3.96M | $1.32M | $72 | $97 |
| FY2023 | $2.94M | $2.90M | $630.06K | $56 | $98 |
| FY2022 | $3.61M | $3.56M | $803.85K | $76 | $100 |
| FY2021 | $4.00M | $3.69M | $943.33K | $112 | $121 |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Executive compensation, fiscal 2026
Summary compensation table from the latest proxy statement
| Executive | Salary | Bonus | Stock awards | Incentive pay | Other | Total | vs. prior year |
|---|---|---|---|---|---|---|---|
| Jack C. Bendheim Chairman of the Board and Executive Chairman | $2.44M | – | $424.26K | $1.59M | $775.35K | $5.23M | -1% |
| Daniel M. Bendheim President and Chief Executive Officer | $575.00K | – | $99.87K | $373.75K | $71.48K | $1.12M | +0% |
| Glenn David Chief Financial Officer | $702.77K | – | $122.06K | $456.80K | $52.09K | $1.33M | +5% |
| Larry L. Miller Chief Operating Officer | $751.85K | $1.06M | $130.60K | $488.70K | $66.97K | $2.50M | +3% |
| Judith Weinstein Senior Vice President, General Counsel and Corporate Secretary | $500.00K | – | $86.84K | $325.00K | $63.35K | $975.19K | -7% |
Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.
Employees
Headcount reported in annual reports
“As of June 30, 2026, we had approximately 2,605 employees in 75 locations spanning 37 countries.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Oct 31, 2024 | Acquisition / sale | Completion of acquisition or disposition of assets (8-K Item 2.01) |
| Jan 25, 2016 | Acquisition / sale | Completion of acquisition or disposition of assets (8-K Item 2.01) |
| Apr 8, 2014 | Listing | Registration of securities on an exchange (Form 8-A) |
| Jul 26, 2006 | Deregistration | Termination of SEC registration (Form 15) |
| Feb 15, 2005 | Late filing | Notification of late filing |
| Jan 14, 2005 | Merger | Registration of securities for a merger or exchange offer (S-4) |
| Feb 18, 2004 | Merger | Registration of securities for a merger or exchange offer (S-4) |
| May 14, 2003 | Name change | Name changed from PHILIPP BROTHERS CHEMICALS INC to Phibro Animal Health Corp |
| Sep 30, 2002 | Late filing | Notification of late filing |
| Sep 28, 2001 | Late filing | Notification of late filing |
| Sep 29, 1998 | Merger | Registration of securities for a merger or exchange offer (S-4) |
See a number that looks wrong?